Prelude Therapeutics Appoints Oncology Veteran Charles Morris As Chief Medical Officer

Prelude Therapeutics has announced the appointment of Charles Morris, M.D., as Chief Medical Officer, effective April 20, 2026. The move strengthens the company’s leadership as it advances its oncology pipeline and clinical development strategy.

Dr. Morris brings more than 30 years of experience in oncology drug development, having worked across global biotech and pharmaceutical companies and contributed to multiple drug approvals. He most recently served as Chief Medical Officer at Lava Therapeutics, and previously held leadership roles at Celyad Oncology and Radius Health.

“We are thrilled to welcome Dr. Charles Morris to Prelude Therapeutics as Executive Vice President and Chief Medical Officer,” stated Kris Vaddi, Chief Executive Officer of Prelude Therapeutics. “With our two lead programs targeting myeloproliferative neoplasms and ER+ breast cancer advancing expected to enter into clinical development in 2026, Dr. Morris’s deep clinical experience, track record of developing successful oncology medicines and proven leadership will be instrumental in ensuring we execute these programs with both rigor and strategic insight.”

Throughout his career, Dr. Morris has played key roles in the development of several oncology therapies, including ORSERDU for breast cancer and ELAHERE for ovarian cancer. He also contributed to clinical programs at ImmunoGen and Allos Therapeutics, and earlier in his career held leadership roles at AstraZeneca, including overseeing the global medical strategy for Faslodex.

“I am excited to join Prelude Therapeutics at this important point in its evolution to help advance its innovative pipeline of novel cancer therapeutics,” stated Charles Morris, MCChB, MRCP, Chief Medical Officer of Prelude Therapeutics. “With the strong science and thorough understanding of the unmet needs that have driven these programs, I see a real opportunity to make an important difference for patients.”

Dr. Morris earned his medical degree from University of Sheffield and is a member of the Royal College of Physicians. In his new role, he will lead clinical development efforts and help drive Prelude’s precision oncology programs forward.